These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 17722967)

  • 1. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
    Karalliedde J; Buckingham RE
    Drug Saf; 2007; 30(9):741-53. PubMed ID: 17722967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
    Goltsman I; Khoury EE; Winaver J; Abassi Z
    Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
    Hollenberg NK
    Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma agonists: safety issues in heart failure.
    Tang WH; Maroo A
    Diabetes Obes Metab; 2007 Jul; 9(4):447-54. PubMed ID: 17587386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
    Scheen AJ
    Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
    Granberry MC; Hawkins JB; Franks AM
    Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of various diuretic treatments on rosiglitazone-induced fluid retention.
    Karalliedde J; Buckingham R; Starkie M; Lorand D; Stewart M; Viberti G;
    J Am Soc Nephrol; 2006 Dec; 17(12):3482-90. PubMed ID: 17093067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinedione-induced congestive heart failure.
    Cheng AY; Fantus IG
    Ann Pharmacother; 2004 May; 38(5):817-20. PubMed ID: 15039476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
    Lago RM; Singh PP; Nesto RW
    Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do thiazolidinediones cause heart failure? A critical review.
    Tang WH
    Cleve Clin J Med; 2006 Apr; 73(4):390-7. PubMed ID: 16610400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
    Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones and PPARγ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
    Vasudevan AR; Balasubramanyam A
    Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.
    Fu Y; Gerasimova M; Batz F; Kuczkowski A; Alam Y; Sanders PW; Ronzaud C; Hummler E; Vallon V
    Nephron; 2015; 129(1):68-74. PubMed ID: 25531136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.